|
A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
RECRUITINGSponsored by ARCE Therapeutics, Inc.
Actively Recruiting
SponsorARCE Therapeutics, Inc.
Started2026-05-12
Est. completion2040-05-30
Eligibility
Healthy vol.Accepted
Locations3 sites
View on ClinicalTrials.gov →
NCT06906380
Summary
This study will evaluate the long-term safety of ARD103 cellular therapies
Eligibility
Healthy volunteers accepted
Inclusion Criteria: * The participant has R/R AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study. * The participant is able to understand and comply with protocol-required study procedures and has provided a written informed consent document. Exclusion Criteria: * There are no specific exclusion criteria for this study
Conditions4
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, in Relapsed or RefractoryCancerMDS (Myelodysplastic Syndrome)
Locations3 sites
North Carolina
2 sitesNovant Health Cancer Institute
Novant Health Cancer Institute
Texas
1 siteFind trials near these locations
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorARCE Therapeutics, Inc.
Started2026-05-12
Est. completion2040-05-30
Eligibility
Healthy vol.Accepted
Locations3 sites
View on ClinicalTrials.gov →
NCT06906380